Credit Suisse Upgrades BioMarin Pharmaceutical (BMRN) to Overweight
BMRN Hot Sheet
Rating Summary:7 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 9 | New: 26
Credit Suisse upgrades BioMarin Pharmaceutical (Nasdaq: BMRN) from Neutral to Overweight. Price target increased from $19 to $25.
To see more analyst ratings on BMRN Click Here.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions.
To see more analyst ratings on BMRN Click Here.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions.
You May Also Be Interested In
- Guggenheim Initiates Coverage on Several Oil & Gas Drilling & Exploration Stocks; Upgrades DO & ESV, Lowers RDC
- Goldman Sachs Upgrades Manitowoc (MTW) to Buy, Sees Trough Valuation
- Needham & Company Maintains a 'Buy' on PetSmart (PETM); Raising PT and Estimates as EPS And SSS Beat Expectations
Create E-mail Alert Related Categories
UpgradesRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
